CHR most commonly stands for “Clinical High Risk” in medical literature, particularly in psychiatry, where it identifies individuals showing early warning signs that they may develop a psychotic disorder such as schizophrenia. Outside of psychiatry, the same three letters appear in ophthalmology (as part of CHRPE, or Congenital Hypertrophy of the Retinal Pigment Epithelium), in oncology shorthand for the chronic phase of certain blood cancers, and in biostatistics as the Cumulative Hazard Ratio. Which meaning applies depends entirely on the clinical context, and that ambiguity is itself a recognized patient-safety problem worth understanding.
Clinical High Risk for Psychosis
The use of CHR that dominates current medical research refers to people at clinical high risk for developing psychosis. You will often see it written as CHR-P, with the “P” specifying psychosis. The concept grew out of nearly a century of attempts to catch schizophrenia and related disorders before they fully emerge. Early efforts tried to reconstruct the “prodrome,” the period of subtle changes before a first psychotic episode, but those efforts could only confirm the prodrome after the person had already become psychotic, which made them useless for prevention.
That changed in the 1980s and 1990s, when researchers developed prospective screening approaches that could identify people who were still in a pre-psychotic state and follow them forward in time.
1Academic Press. Historical perspectives on psychosis riskThe CHR designation is now mainly established by the presence of attenuated positive symptoms: perceptual experiences or unusual thoughts that resemble hallucinations and delusions but are milder, less frequent, and still partially recognized by the person experiencing them as unusual.
2European Psychiatry. Attenuated positive and negative symptoms in patients at clinical high-risk for psychosisThere is also growing attention to attenuated negative symptoms, things like social withdrawal, flattened emotional expression, and reduced motivation, which play their own role in predicting who eventually develops a full psychotic disorder.
How Clinicians Assess CHR Status
Two semi-structured interview tools dominate CHR assessment worldwide. The Comprehensive Assessment of At-Risk Mental States (CAARMS) and the Structured Interview for Psychosis-Risk Syndromes (SIPS) are the most widely used instruments for defining whether someone meets CHR criteria.
3PubMed. Harmonizing the structured interview for psychosis-risk syndromes (SIPS) and the comprehensive assessment of at-risk mental states (CAARMS): An initial approachThe CAARMS covers 27 items across seven subscales, rating the intensity and frequency of symptoms like unusual thought content, perceptual abnormalities, cognitive changes, emotional disturbances, and negative symptoms. Positive symptoms on the CAARMS are the key items used both to determine whether someone meets the CHR threshold and to decide when they have crossed the line into frank psychosis.
4PubMed Central. Identification and predictive analysis for participants at ultra-high risk of psychosis: A comparison of three psychometric diagnostic interviewsThe SIPS takes a somewhat different structural approach, bundling a family history questionnaire, a psychosis-risk symptom scale, a global functioning assessment, and a schizotypal personality checklist into one package. Both instruments aim at the same goal, and researchers have been working to harmonize them so results from studies using one can be compared with studies using the other.
Neither tool is a blood test or a brain scan. They rely on a trained clinician conducting an in-depth interview, which means the accuracy of the CHR label depends heavily on the skill and experience of the person administering the assessment. In practice, this means CHR identification happens mostly in specialized early-intervention clinics rather than in a general practitioner’s office.
What Happens After a CHR Designation
Getting labeled CHR does not mean psychosis is inevitable. Conversion rates, the proportion of CHR individuals who go on to develop a full psychotic disorder, are lower than many people assume. Across studies, conversion to psychosis among CHR youth has been reported at roughly 15 to 35 percent over three years.
5PubMed Central. A Review of Potential Neuroimaging Biomarkers of Schizophrenia-RiskThat means the majority of people who meet CHR criteria never develop schizophrenia or a related disorder, at least not within the follow-up windows that studies have measured.
The picture looks even more favorable in younger populations. A meta-analysis found that CHR children and adolescents had a conversion rate of about 9.5 percent at one year, compared with roughly 18 percent in CHR adults.
6PubMed Central. Clinical profile, conversion rate, and suicidal thinking and behaviour in children and adolescents at ultra-high risk for psychosis: a theoretical perspectiveIn one study of 35 CHR youth followed for a year, a fifth developed schizophrenia, about a quarter fully remitted from their CHR status, and over half remained in the CHR zone without getting better or worse. This tells us that the CHR state can be quite stable in young people, lingering without progressing, which creates its own clinical challenge: how long do you monitor someone, and when do you stop worrying?
Interventions for People at Clinical High Risk
Because most CHR individuals do not convert to psychosis, treatment decisions are tricky. You do not want to prescribe antipsychotic medications to someone who may never need them, but you also do not want to miss the window for early help. The evidence for specific interventions is modest but points in some useful directions.
Cognitive behavioral therapy (CBT) has the strongest track record. Meta-analyses have found that CBT reduces the risk of conversion to psychosis at 12 and 18 months compared to other interventions. A comprehensive meta-analysis looking specifically at transition to psychosis as the primary outcome found that the pooled effect of CBT at 12 months was significantly greater than comparable treatments.
7PubMed Central. Recent Updates on Predicting Conversion in Youth at Clinical High Risk for PsychosisOmega-3 fatty acid supplements generated early excitement after a single trial suggested they lowered conversion rates, but a larger follow-up trial (the NEURAPRO trial) was unable to replicate that finding. This is a good example of why initial promising results in psychiatry need replication before they change clinical practice. As it stands, CBT is the intervention with the most consistent evidence for helping CHR individuals, though the effect sizes are not enormous and no intervention has been shown to definitively prevent psychosis in every person at risk.
Brain Imaging and Future Prediction
Researchers are actively searching for brain-based markers that could improve the accuracy of predicting who among CHR individuals will actually convert to psychosis. Neuroimaging studies have used structural MRI, functional connectivity scans, diffusion imaging, PET scans, and other modalities to look for differences between CHR individuals who convert and those who do not.
5PubMed Central. A Review of Potential Neuroimaging Biomarkers of Schizophrenia-RiskThe risk for developing schizophrenia is already elevated among first-degree relatives of people with psychotic disorders, but it is even higher in those who also meet CHR criteria. The hope is that brain scans could eventually be layered on top of clinical interviews to create more precise risk profiles. For now, though, no single neuroimaging marker has proven reliable enough for routine clinical use. The field is still in the discovery phase, identifying candidate biomarkers and testing them across different populations. If you encounter CHR in the context of a neuroimaging study, it almost certainly refers to this clinical high risk for psychosis construct.
CHR in Ophthalmology
Step outside psychiatry and CHR takes on completely different meanings. In ophthalmology, you are most likely to encounter it as part of CHRPE, which stands for Congenital Hypertrophy of the Retinal Pigment Epithelium. These are flat, darkly pigmented patches on the retina that are present from birth. They are usually discovered incidentally during a routine eye exam because they rarely cause symptoms or affect vision.
CHRPE lesions are not rare. One study of an optometric population found a prevalence of about 1.2 percent, with lesions most commonly located on the temporal side of the optic disc in the peripheral retina. They were roughly evenly divided between those with and without depigmented haloes and internal gaps called lacunae, and all were found in only one eye.
8Wiley Online Library. Congenital hypertrophy of the retinal pigment epithelium: prevalence and ocular features in the optometric populationSolitary CHRPE lesions are almost always benign and need nothing more than periodic monitoring. Where things get clinically interesting is when multiple bilateral CHRPE lesions appear, because this pattern can be a marker for Gardner syndrome, a hereditary condition associated with a specific gene mutation that also causes widespread intestinal polyps and carries a high risk of colorectal cancer. Genetic studies have shown tight linkage between the Gardner syndrome mutation and the CHRPE trait, meaning CHRPE can serve as an early and visible flag for a condition that might otherwise go undiagnosed until serious intestinal problems develop.
9PubMed Central. A genetic study of Gardner syndrome and congenital hypertrophy of the retinal pigment epitheliumIn families where Gardner syndrome is known to run, an ophthalmologist spotting CHRPE in a young family member can trigger earlier and more aggressive screening for intestinal polyps, potentially catching cancer risk years before symptoms appear.
CHR in Oncology and Biostatistics
In oncology, CHR sometimes appears as shorthand for “complete hematologic response” or “chronic” when discussing chronic-phase leukemia, particularly chronic myelogenous leukemia (CML). CML progresses through distinct phases, and treatment outcomes are often reported in terms of how many patients achieve a complete hematologic response, meaning their blood counts and bone marrow return to normal. In a landmark trial of imatinib (a targeted therapy that transformed CML treatment), 95 percent of patients with confirmed chronic-phase CML achieved a complete hematologic response.
10PubMed. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaIn biostatistics and epidemiology, CHR can also refer to the Cumulative Hazard Ratio, a statistical measure used in clinical trials to compare the cumulative risk of an event (like disease progression or death) between different treatment groups over time.
11PubMed Central. Cumulative Hazard Ratio Estimation for Treatment Regimes in Sequentially Randomized Clinical TrialsYou are unlikely to encounter this version of CHR unless you are reading the methods or results section of a clinical trial paper. For patients reading their own records or lab results, this statistical use of CHR is rarely relevant.
Why the Same Abbreviation Can Mean So Many Things
The fact that CHR can mean clinical high risk, congenital hypertrophy of the retinal pigment epithelium, complete hematologic response, or cumulative hazard ratio is not an oddity. It is a symptom of a systemic problem in medicine. Research on medical abbreviations has consistently found that a large proportion of them carry multiple meanings that shift based on specialty, department, or even which hospital you are in.
One study found that close to a third of abbreviations used in general medical discharge summaries were ambiguous, appearing with more than one possible meaning.
12PubMed. Ambiguous medical abbreviation study: challenges and opportunitiesAnother survey tested healthcare volunteers on 20 common medical abbreviations and found that only four of them (20 percent) were correctly interpreted by more than half the volunteers. Three-quarters of the abbreviations had at least one alternative definition, and some had as many as seven.
13PubMed Central. Interpretation and Misinterpretation of Medical Abbreviations Found in Patient Medical Records: A Cross-Sectional SurveyThis is not just an academic curiosity. Ambiguous abbreviations contribute to an estimated 13 percent of medication errors.
14PubMed. When shortcuts fall short: The hidden danger of abbreviations in critical careWhen a nurse on one ward reads “CHR” and interprets it differently from the specialist who wrote it, the consequences can range from confusion to genuine harm. Strategies to reduce this risk include spelling out terms at their first use, maintaining standardized abbreviation lists within each hospital unit, and training staff in closed-loop communication where the receiver confirms back what they understood.
Reading Your Own Medical Records
If you are a patient trying to decode an abbreviation like CHR in your own chart, the specialty of the doctor who wrote it is your best clue. A psychiatrist’s note almost certainly means clinical high risk. An ophthalmologist’s report likely refers to CHRPE. An oncologist treating leukemia might be using it for chronic-phase or complete hematologic response. And a statistical table in a research report is probably talking about the cumulative hazard ratio.
Patient portals have made it easier to access lab results and clinical notes, which helps people prepare for appointments and communicate better with their providers. But that access also means encountering more unexplained abbreviations than ever before. If you see CHR or any other abbreviation in your records and are not sure what it means, asking your provider to clarify is always reasonable and worth the brief conversation.
How Computers Are Tackling Abbreviation Ambiguity
The sheer volume of ambiguous abbreviations in electronic health records has made this a target for automated solutions. Natural language processing systems have been trained to look at the surrounding words in a clinical note and predict which meaning of an abbreviation the writer intended. Early approaches used machine-learning methods like support vector machines and decision trees trained on large collections of labeled examples.
15PubMed Central. Automated disambiguation of acronyms and abbreviations in clinical texts: window and training size considerationsMore recently, large language models have entered the picture. In experiments testing GPT-4’s ability to disambiguate clinical acronyms without any prior training on the specific dataset (a “zero-shot” approach), the model achieved accuracy as high as 0.978, matching or exceeding the performance of earlier purpose-built systems.
16Journal of the American Medical Informatics Association. Disambiguation of acronyms in clinical narratives with large language modelsOther researchers have used deep learning approaches that incorporate medical ontologies, essentially giving the algorithm an understanding of how medical concepts relate to each other, to improve its guesses about what an abbreviation means in context.
17Nature Communications. Automatically disambiguating medical acronyms with ontology-aware deep learningThese tools are not yet standard in most hospital electronic health record systems, but they point toward a future where clinical notes could automatically expand abbreviations into their full terms, reducing the chance that a three-letter shortcut like CHR leads to a three-way misunderstanding. For now, the burden of figuring out which CHR you are looking at still falls on the reader and the context they bring to the page.